Yazar "Demirci, Ufuk" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study
    (Springer Science and Business Media Deutschland GmbH, 2022) Demirci, Ufuk; Kırkızlar, Hakkı Onur; Ümit, Elif Gülsüm; Gürsoy, Vildan; Pınar, İbrahim Ethem; Özkalemkaş, Fahir; Güven, Zeynep Tuğba; Kaynar, Leylagül; Keklik Karadağ, Fatma; Saydam, Güray; Ekinci, Ömer; Merter, Mustafa; Aras, Merih Reis; Albayrak, Murat; Karaman Gülsaran, Sedanur; Baş, Volkan; Balık Aydın, Berrin; Beköz, Hüseyin Saffet; Can, Ferda; Dilek, İmdat; Mehtap, Özgür; Öztürk, Erman; Çobanoğlu Şimşek, Bengü; Yıldırım, Murat; Aylı, Meltem; Ataş, Ünal; Salim, Ozan; Ayer, Mesut; Birtaş Ateşoğlu, Elif; Akay, Olga Meltem; Kurt Yüksel, Meltem; Paydaş, Semra; Korkmaz, Selçuk; Öz Puyan, Fulya; Demir, Ahmet Muzaffer
    Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality in a specific manner, morphology, and immunohistochemistry remain the backbone. We aimed to evaluate the value of CD5 expression on disease characteristics as well as prognosis in patients with DLBCL. Data of 131 patients with DLBCL with CD5 positivity and as a comparison arm, data of 129 patients with DLBCL without CD5 positivity were evaluated. Mean age was 59 and 55.7% of the patients were male. Overall survival was 29.8 months. Poor prognostic factors including (high-LDH levels, B symptoms, low ECOG score, high R-IPI and NCCN-IPI score) were observed to be significantly related with CD5 positivity. Mean survival in CD5 positive patients were 29.8 months, which is significantly shorter than the general DLBCL survival worldwide. CD5 expression shall be evaluated in all samples of DLBCL patients due to its possible effects on outcomes.
  • Küçük Resim
    Öğe
    Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies
    (NLM (Medline), 2022) Civriz Bozdağ, Sinem; Cengiz Seval, Güldane; Yönal Hindilerden, İpek; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Aydın Kanyar, Lale; Toprak, Selami Koçak; Göksoy, Hasan Sami; Balık Aydın, Berrin; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Özkurt, Zübeyde Nur; Demircioğlu, Sinan; Beksaç, Meral; İnce, İdris; Yılmaz, Umut; Eroğlu Küçükdiler, Hilal; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yaşa Gül; Baş, Volkan; Özkalemkaş, Fahir; Üsküdar Teke, Hava; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yegin, Zeynep Arzu; Kurt Yüksel, Meltem; Sadri, Soğol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Bolaman, Ali Zahit; Sevindik, Ömür Gökmen; Akyay, Arzu; Özcan, Muhit; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Diz Küçükkaya, Reyhan; Özsan, Güner Hayri
    Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARS-CoV- 2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixty-nine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.
  • Küçük Resim
    Öğe
    Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
    (Oxford University Press, 2019) Kılıçkap, Saadettin; Buğdaycı Basal, Fatma; Demirkazık, Ahmet; Gürsoy, Pınar; Demirci, Ufuk; Erman, Mustafa; Yumuk, Fulden; Çay Şenler, Filiz; Çakar, Burcu; Çiçin, İrfan; Öztürk, Akın; Coşkun, Hasan Şenol; Çubukçu, Erdem; Işıkdoğan, Abdurrahman; Ölmez, Ömer Fatih; Tatlı, Ali Murat; Karaağaç, Mehmet Onur; Sakalar, Teoman; Eralp, Yeşim; Korkmaz, Taner
    Background: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK? patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK?patients who have Ple-I/E. Methods: In this multicenter study, patients with ALK? NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALK?patients with NSCLC. Results: Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p¼0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p¼0.541). The rate of smokers was 43.4% (n¼157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p¼0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALK?patients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p¼0.008; 19.1% vs 4.8%, p¼0.002; 20.6% vs 8.9%, p¼0.003). The median PFS was longer in ALK? patients who have Ple-I/E 18.7 vs 10.6 months, p¼0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALK?patients who have pleural involvement/infusion 44.6 vs 22.6 months, p¼0.051). The 1-, 2- and 3- year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement. Conclusions: Brain, liver and bone metastases are lower in ALK?patients with Ple-I/E. Presentation with Ple-I/E in patients with ALK? NSCLC is associated with longer overall and progression-free survival. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.